GGrantIndex
← Leaderboards

Pamela Fitch Weiss

Children'S Hosp Of Philadelphia

$3,661,080
Attributed
$3,661,080
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $599.2K · FY200725
$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$3,661,080 · 6

By mechanism

R01$2,212,644 · 2
K23$609,798 · 1
K24$530,860 · 1
R03$219,528 · 1
F32$88,250 · 1

Top collaborators

No co-investigators on record.

Most similar at Children'S Hosp Of Philadelphia

Same institution · by research overlap

Others in their field

Top investigators on “Inflammation

Research focus

InflammationChildChildhoodArthritisAccountingChronic Childhood ArthritisPreventInflammatoryPredictive ValuePharmaceutical PreparationsAdultJointsSacroiliac Joint StructureMorbidity - Disease RateDiagnosisAdolescentImageRecording Of Previous EventsFutureRheumatologyDisease RemissionAnkylosing SpondylitisCohortClinical Trials

Grant awards (22)

Immunological, serologic, and imaging biomarker predictors of flare in pediatric spondyloarthritis$364,553
R01 · FY2025 · AR · contact PI
Mentoring and Patient Oriented Research in Juvenile Spondyloarthritis$132,715
K24 · FY2025 · AR · contact PI
Immunological, serologic, and imaging biomarker predictors of flare in pediatric spondyloarthritis$377,034
R01 · FY2024 · AR · contact PI
Mentoring and Patient Oriented Research in Juvenile Spondyloarthritis$132,715
K24 · FY2024 · AR · contact PI
Mentoring and Patient Oriented Research in Juvenile Spondyloarthritis$132,715
K24 · FY2023 · AR · contact PI
Immunological, serologic, and imaging biomarker predictors of flare in pediatric spondyloarthritis$382,026
R01 · FY2022 · AR · contact PI
Mentoring and Patient Oriented Research in Juvenile Spondyloarthritis$132,715
K24 · FY2022 · AR · contact PI
Immunological, serologic, and imaging biomarker predictors of flare in pediatric spondyloarthritis$411,417
R01 · FY2021 · AR · contact PI
Refining entry criteria and outcome measures for children with axial disease and spondyloarthritis: preparation for clinical trials$187,792
R01 · FY2021 · AR · contact PI
Refining entry criteria and outcome measures for children with axial disease and spondyloarthritis: preparation for clinical trials$186,634
R01 · FY2020 · AR · contact PI
Refining entry criteria and outcome measures for children with axial disease and spondyloarthritis: preparation for clinical trials$303,188
R01 · FY2019 · AR · contact PI
Evaluation and treatment of enthesitis-related arthritis$116,450
K23 · FY2015 · AR · contact PI
Evaluation and treatment of enthesitis-related arthritis$116,450
K23 · FY2014 · AR · contact PI
Sacroiliitis in early ERA$82,075
R03 · FY2014 · AR · contact PI
Evaluation and treatment of enthesitis-related arthritis$515
K23 · FY2014 · AR · contact PI
Evaluation and treatment of enthesitis-related arthritis$125,577
K23 · FY2013 · AR · contact PI
Sacroiliitis in early ERA$68,178
R03 · FY2013 · AR · contact PI
Evaluation and treatment of enthesitis-related arthritis$125,505
K23 · FY2012 · AR · contact PI
Sacroiliitis in early ERA$69,275
R03 · FY2012 · AR · contact PI
Evaluation and treatment of enthesitis-related arthritis$125,301
K23 · FY2011 · AR · contact PI
Henoch Schonlein Purpura and Corticosteroid Treatment$20,041
F32 · FY2008 · DK · contact PI
Henoch Schonlein Purpura and Corticosteroid Treatment$68,209
F32 · FY2007 · DK · contact PI